​

Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$492.83

52W Range

$271.96 - $615.00

50D Avg

$514.80

200D Avg

$489.39

Market Cap

$11.23B

Avg Vol (3M)

$318.12K

Beta

-1.06

Div Yield

-

MDGL Company Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

528

IPO Date

Feb 06, 2007

Website

MDGL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25
Reportable Segment$958.40M

Fiscal year ends in Dec 25 | Currency in USD

MDGL Financial Summary

Dec 25Dec 24Dec 23
Revenue$958.40M$180.13M-
Operating Income$-300.10M$-497.88M$-380.50M
Net Income$-288.28M$-465.89M$-373.63M
EBITDA$-300.10M$-450.13M$-360.39M
Basic EPS$-12.85$-21.90$-19.99
Diluted EPS$-12.85$-21.90$-19.99

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 06, 26 | 12:00 AM
Q4 25Feb 19, 26 | 12:00 AM
Q3 25Nov 04, 25 | 8:00 AM

Peer Comparison

TickerCompany
CAICaris Life Sciences, Inc.
JAZZJazz Pharmaceuticals plc
BAXBaxter International Inc.
TECHBio-Techne Corporation
RYTMRhythm Pharmaceuticals, Inc.
EXELExelixis, Inc.
ABVXAbivax S.A.
RNAAtrium Therapeutics, Inc.
MRNAModerna, Inc.
BMRNBioMarin Pharmaceutical Inc.